Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.

Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.

A method for treating a medical condition of a patient with at least Alpha-2 Macroglobulin (2M) molecules in an allogeneic or xenogeneic manner includes: drawing whole blood from a donor; separating platelet poor plasma (PPP) containing 2M molecules from other components of the whole blood; filtering waste plasma from the PPP to generate an aggregate of the 2M molecules; and administering at least some of the aggregate to the patient via injection or inhalation, wherein the donor and the patient are different individuals.

A method for treating a respiratory condition of a patient with at least Alpha-2 Macroglobulin (2M) molecules includes: drawing whole blood; separating platelet poor plasma (PPP) containing 2M molecules from other components of the whole blood; filtering waste plasma from the PPP to generate an aggregate of the 2M molecules; and administering at least some of the aggregate to the patient via inhalation.

The present disclosure relates to a drug-device combination comprising a liquid solution (26) containing a biologic; and a nebulizer (10) for aerosolization of the liquid solution (26), the nebulizer (10) comprising a reservoir (24) for holding the liquid solution (26), the reservoir (24) having a vent (48) for maintaining atmospheric pressure in the reservoir (24), a vibratable membrane (60) having an active area (62) with apertures (110), wherein the liquid solution (26) is feedable to the active area (62) at a liquid side (64) of the membrane (60), a piezoelectric actuator for vibrating the membrane (60), whereby an aerosol of the liquid solution (26) is generated at the active area (62) at an aerosol side (66) of the membrane (60), the aerosol side (66) of the membrane (60) being opposite to the liquid side (64) of the membrane (60) and a plenum chamber (23) having an inlet (76) at an inlet side at the aerosol side (66) of the membrane (60) and an outlet (94) at an outlet side for administering the aerosol, the outlet (94) of the plenum chamber being opposite to the inlet (76) of the plenum chamber (23).